Emergent BioSolutions stock jumps 19.6% on suspected plague death in Russia

Emergent BioSolutions' stock surged nearly 19.6% to $7.57 in afternoon trading after a suspected plague death at Russia's Irkutsk Anti-Plague Research Institute in Siberia drove investors toward biodefense-related stocks. The suspected outbreak prompted U.S. Secretary of State Marco Rubio and the State Department to closely monitor the situation, with officials coordinating with the CDC and urging Moscow to share accurate information. The biodefense angle is significant for Emergent given its portfolio of approved medical countermeasures, while local Russian authorities placed at least 197 potential contacts under medical observation. The stock's rise also reflects strong recent operational results, including adjusted earnings per share of $0.60 versus an expected loss, and revenue of $234.3 million beating consensus estimates. Analysts maintain a "Hold" rating with a $10.00 price target, while the broader market provided a supportive backdrop with the S&P 500 up 0.7%.